Details
| Original language | English |
|---|---|
| Pages (from-to) | 858-864 |
| Number of pages | 7 |
| Journal | Nutrition, Metabolism and Cardiovascular Diseases |
| Volume | 27 |
| Issue number | 10 |
| Early online date | 11 Jul 2017 |
| Publication status | Published - Oct 2017 |
| Externally published | Yes |
Abstract
Background & aims 3-Hydroxyisobutyrate (3-HIB), a catabolic intermediate of the BCAA valine, which stimulates muscle fatty acid uptake, has been implicated in the pathogenesis of insulin resistance. We tested the hypothesis that circulating 3-HIB herald insulin resistance and that metabolic improvement with weight loss are related to changes in BCAAs and 3-HIB. Methods and results We analyzed plasma and urine in 109 overweight to obese individuals before and after six months on hypocaloric diets reduced in either carbohydrates or fat. We calculated the homeostasis model assessment index (HOMA-IR) and whole body insulin sensitivity from oral glucose tolerance tests and measured intramyocellular fat by magnetic resonance spectroscopy. BCAAs and 3-HIB plasma concentrations were inversely related to insulin sensitivity but not to intramyocellular fat content at baseline. With 7.4 ± 4.5% weight loss mean BCAA and 3-HIB plasma concentrations did not change, irrespective of dietary macronutrient content. Individual changes in 3-HIB with 6-month diet but not BCAAs were correlated to the change in whole body insulin sensitivity and HOMA-IR independently of BMI changes. Conclusions 3-HIB relates to insulin sensitivity but is not associated with intramyocellular fat content in overweight to obese individuals. Moreover, changes in 3-HIB rather than changes in BCAAs are associated with metabolic improvements with weight loss. Registration number for clinical trials: ClinicalTrials.gov Identifier: NCT00956566.
Keywords
- Insulin sensitivity, Intramyocellular fat, Weight loss
ASJC Scopus subject areas
- Medicine(all)
- Medicine (miscellaneous)
- Medicine(all)
- Endocrinology, Diabetes and Metabolism
- Nursing(all)
- Nutrition and Dietetics
- Medicine(all)
- Cardiology and Cardiovascular Medicine
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 27, No. 10, 10.2017, p. 858-864.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals
AU - Haufe, S.
AU - Engeli, S.
AU - Kaminski, J.
AU - Witt, H.
AU - Rein, D.
AU - Kamlage, B.
AU - Utz, W.
AU - Fuhrmann, J. C.
AU - Haas, V.
AU - Mähler, A.
AU - Schulz-Menger, J.
AU - Luft, F. C.
AU - Boschmann, M.
AU - Jordan, J.
N1 - Funding Information: We thank Gritt Stoffels, Anke Strauss, and Elke Nickel-Sczcech for expert technical help with patient recruitment and study procedures. This study was part of a joint project between Metanomics GmbH (Berlin, Germany) and Charité – University Medical School, which was supported by the Federal Ministry of Education and Research ( BMBF–0313868 ), and the German Obesity Network of Competence ( 01 Gl0830 ).
PY - 2017/10
Y1 - 2017/10
N2 - Background & aims 3-Hydroxyisobutyrate (3-HIB), a catabolic intermediate of the BCAA valine, which stimulates muscle fatty acid uptake, has been implicated in the pathogenesis of insulin resistance. We tested the hypothesis that circulating 3-HIB herald insulin resistance and that metabolic improvement with weight loss are related to changes in BCAAs and 3-HIB. Methods and results We analyzed plasma and urine in 109 overweight to obese individuals before and after six months on hypocaloric diets reduced in either carbohydrates or fat. We calculated the homeostasis model assessment index (HOMA-IR) and whole body insulin sensitivity from oral glucose tolerance tests and measured intramyocellular fat by magnetic resonance spectroscopy. BCAAs and 3-HIB plasma concentrations were inversely related to insulin sensitivity but not to intramyocellular fat content at baseline. With 7.4 ± 4.5% weight loss mean BCAA and 3-HIB plasma concentrations did not change, irrespective of dietary macronutrient content. Individual changes in 3-HIB with 6-month diet but not BCAAs were correlated to the change in whole body insulin sensitivity and HOMA-IR independently of BMI changes. Conclusions 3-HIB relates to insulin sensitivity but is not associated with intramyocellular fat content in overweight to obese individuals. Moreover, changes in 3-HIB rather than changes in BCAAs are associated with metabolic improvements with weight loss. Registration number for clinical trials: ClinicalTrials.gov Identifier: NCT00956566.
AB - Background & aims 3-Hydroxyisobutyrate (3-HIB), a catabolic intermediate of the BCAA valine, which stimulates muscle fatty acid uptake, has been implicated in the pathogenesis of insulin resistance. We tested the hypothesis that circulating 3-HIB herald insulin resistance and that metabolic improvement with weight loss are related to changes in BCAAs and 3-HIB. Methods and results We analyzed plasma and urine in 109 overweight to obese individuals before and after six months on hypocaloric diets reduced in either carbohydrates or fat. We calculated the homeostasis model assessment index (HOMA-IR) and whole body insulin sensitivity from oral glucose tolerance tests and measured intramyocellular fat by magnetic resonance spectroscopy. BCAAs and 3-HIB plasma concentrations were inversely related to insulin sensitivity but not to intramyocellular fat content at baseline. With 7.4 ± 4.5% weight loss mean BCAA and 3-HIB plasma concentrations did not change, irrespective of dietary macronutrient content. Individual changes in 3-HIB with 6-month diet but not BCAAs were correlated to the change in whole body insulin sensitivity and HOMA-IR independently of BMI changes. Conclusions 3-HIB relates to insulin sensitivity but is not associated with intramyocellular fat content in overweight to obese individuals. Moreover, changes in 3-HIB rather than changes in BCAAs are associated with metabolic improvements with weight loss. Registration number for clinical trials: ClinicalTrials.gov Identifier: NCT00956566.
KW - Insulin sensitivity
KW - Intramyocellular fat
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=85029813489&partnerID=8YFLogxK
U2 - 10.1016/j.numecd.2017.07.001
DO - 10.1016/j.numecd.2017.07.001
M3 - Article
C2 - 28958691
AN - SCOPUS:85029813489
VL - 27
SP - 858
EP - 864
JO - Nutrition, Metabolism and Cardiovascular Diseases
JF - Nutrition, Metabolism and Cardiovascular Diseases
SN - 0939-4753
IS - 10
ER -